William Kim, PhD
Assistant Professor, Yale University School of Medicine Department of Urology
- Profile
Profile
Dr. William Kim has demonstrated a passion for interdisciplinary collaboration. His research leverages advanced computational and data-driven approaches alongside genome engineering technologies to contribute to advancing our understanding of cancer. Kim received his PhD from Duke University in 2010 from Duke University where he discovered the novel role of microRNAs in regulating key cell fate determination via Myc and E2F pathways. and the Institute for Genome Sciences Policy, where he received support from the Department of Defense Breast Cancer Research Predoctoral Program and the Korean Science & Engineering Foundation Award.
Following his doctoral work, Kim joined the Dana Farber Cancer Institute and the Broad Institute of Harvard and MIT for his postdoctoral research. There, he made significant contributions to developing novel computational approaches for the systematic characterization of cancer genomes and oncogenic cellular states. He also discovered a novel role for the Protein phosphatase 2A (PP2A) enzyme in oncogenic transformation, expanding the understanding of this important signaling pathway.
Leveraging his expertise in cancer biology and computational biology, Kim then joined the University of California San Diego, School of Medicine in the Division of Genomics and Precision Medicine. At UCSD, he co-led a multidisciplinary team of researchers, clinicians, patients, and community advocates on a California Initiative for Precision Medicine Project, supported by the California Governor's Office. Kim also served as the Co-Director of the UCSD Center for Cancer Target Discovery and Development (CTD2), further driving the integration of data-driven and biological approaches to cancer research.
William Kim then joined the Department of Urology at Yale University School of Medicine. Here, he aims to bridge the gap between cancer biology and data science, working towards a comprehensive understanding of cellular circuitry and the realization of the full potential of cancer precision medicine.
Following his doctoral work, Kim joined the Dana Farber Cancer Institute and the Broad Institute of Harvard and MIT for his postdoctoral research. There, he made significant contributions to developing novel computational approaches for the systematic characterization of cancer genomes and oncogenic cellular states. He also discovered a novel role for the Protein phosphatase 2A (PP2A) enzyme in oncogenic transformation, expanding the understanding of this important signaling pathway.
Leveraging his expertise in cancer biology and computational biology, Kim then joined the University of California San Diego, School of Medicine in the Division of Genomics and Precision Medicine. At UCSD, he co-led a multidisciplinary team of researchers, clinicians, patients, and community advocates on a California Initiative for Precision Medicine Project, supported by the California Governor's Office. Kim also served as the Co-Director of the UCSD Center for Cancer Target Discovery and Development (CTD2), further driving the integration of data-driven and biological approaches to cancer research.
William Kim then joined the Department of Urology at Yale University School of Medicine. Here, he aims to bridge the gap between cancer biology and data science, working towards a comprehensive understanding of cellular circuitry and the realization of the full potential of cancer precision medicine.